PubMed Trending Research Digest — August 26, 2026

Automated digest · 98 articles · 15 research areas · August 26, 2026

Overview

This week’s digest is dominated by immune dysfunction and microenvironment biology across diseases—ranging from sepsis to cancer. Multiple studies dissect how immune cells fail or become maladaptive: neonatal sepsis work maps immune cell dynamics and implicates S100–TLR4–MYD88 circuitry; mechanistic sepsis studies identify macrophage PARP7–TBK1 inflammatory control and circadian disruption pathways that drive monocyte/macrophage immunosuppression. In oncology, spatial and single-cell approaches (e.g., ENKTL macrophage-defined subgroups; IPF fibrotic niche; TIL quantification studies in breast cancer) emphasize that prognosis and therapy response are shaped by structured, communicating cellular ecosystems rather than single biomarkers alone.

A second major theme is precision targeting—both in therapeutics and in how patients are selected. In cancer, several trials and preclinical efforts focus on improving therapeutic windows: safer immunomodulators that uncouple Type I interferon from toxicity, improved nectin-4 ADC designs, and chronobiology-informed timing of tumor-derived extracellular vesicle secretion to enhance targeted therapy. Biomarker-driven strategies also recur, including mutation-guided consolidation in AML, pharmacogenomic variant frequency in pediatric oncology, and refined prognostic/radiation-benefit tools in high-risk cutaneous squamous cell carcinoma. Outside oncology, precision is reflected in genetic/epigenetic mechanism studies (e.g., PIEZO2 mechanotransduction, DDIAS ssDNA protection in HR-deficient tumors, R-loop/epigenetic barrier formation in oocytes) and in neurodegeneration frameworks that unify TDP-43 pathology across syndromes.

Finally, the digest highlights clinically actionable “real-world” and translational signals. Studies address guideline-relevant asthma management in pregnancy and the impact of biologic access on severe asthma outcomes; stroke prevention evidence compares high-intensity statins; and multiple trials report durable or regimen-specific benefits (e.g., adjuvant olaparib in BRCA-associated breast cancer, long-term MAIA follow-up in multiple myeloma, and induction regimen improvements in nasopharyngeal carcinoma). Together, these findings reinforce a broader trend: integrating mechanistic biology with pragmatic clinical implementation—timing, access, dosing, and patient stratification—to translate research into better outcomes.

---

Asthma & Pregnancy Outcomes (ICS, severe asthma access)

Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study.

This global real-world ecological study used severe asthma registry data (CHRONICLE, ISAR, and OPCRD) to examine whether ease of biologic access, quantified by a biologic accessibility score (BACS), is associated with remission and other post-biologic outcomes in severe asthma across 21 countries. The key finding was that countries with easier access to biologics showed better post-initiation clinical outcomes, including higher likelihood of remission. Clinically, it underscores that health-system factors affecting time to biologic initiation can meaningfully influence patient outcomes in severe asthma.

Hansen S, Tsai MJ, Tran TN et al. · Journal of asthma and allergy · (2026) · View on PubMed ↗

Inhaled Corticosteroids Continuation in the First Trimester and Pregnancy Outcomes in Women With Asthma.

This nationwide Korean mother-child cohort study evaluated whether continuing inhaled corticosteroids (ICS) during the first trimester of pregnancy among women with asthma was associated with maternal and neonatal outcomes. First-trimester ICS continuation was associated with improved or comparable pregnancy outcomes versus discontinuation (with the study designed to quantify maternal and perinatal risks). These findings support guideline-recommended ICS continuation in early pregnancy to reduce preventable asthma-related maternal and neonatal complications.

Suh B, Cho Y, Choi EY et al. · JAMA network open · (2026) · View on PubMed ↗

---

Sepsis Biology, Immune Dysfunction & Organ Failure

A single-cell transcriptomic atlas reveals the immune panorama of neonatal sepsis.

This study used single-cell RNA sequencing on blood from 18 neonates (26 samples) across acute neonatal sepsis, convalescence, and healthy controls to map immune cell dynamics. It identified 57 cell subtypes with acute lymphoid depletion and myeloid expansion, including S100A8+ MDSC-like cells implicated as a potential cytokine-storm source via an S100–TLR4–MYD88 feedforward circuit, while innate-like lymphocytes showed apoptosis/exhaustion despite increased cytotoxicity. These findings provide a cellular and pathway-level immune atlas of neonatal sepsis that could guide targeted diagnostics and therapies aimed at both hyperinflammation and immunosuppression.

Wang J, Chen Y, Zou P et al. · Cell reports · (2026) · View on PubMed ↗

Targeting the NR1D1-IGF2BP2-V-ATPase Axis With Hybrid Nanovesicles Restores Macrophage Rhythms to Reverse Sepsis-Induced Immunosuppression.

This study integrated multi-cohort transcriptomic and single-cell datasets, and used septic mice models, to define how circadian disruption drives sepsis-induced immunosuppression in monocytes/macrophages. It found that sustained endotoxin stimulation increases the core clock repressor NR1D1 in macrophages, where NR1D1 occupies the Igf2bp2 promoter to suppress IGF2BP2, leading to m6A-dependent destabilization of V-ATPase transcripts (Atp6v1b2 and Atp6v0c) and impaired macrophage rhythmicity. Targeting the NR1D1–IGF2BP2–V-ATPase axis with hybrid nanovesicles restored macrophage rhythms, supporting a mechanistic and therapeutic strategy to reverse sepsis-associated immune dysfunction.

Chen L, Lin W, Jiang L et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Clinically recognized sepsis in older adults admitted to medical wards: patient characteristics and hospital outcomes from the REPOSI register.

Using the Italian REPOSI registry (2009–2023), this study characterized older adults (≥65 years) with clinically recognized sepsis admitted to internal medicine and geriatric wards and assessed patient characteristics and hospital outcomes. Latent Class Analysis (LCA) identified distinct multimorbidity patterns among sepsis patients, and these patterns were linked to differences in prognosis outside the ICU setting. The results clarify prognostic determinants for sepsis in non-ICU medical wards, informing risk stratification and management of frail, multimorbid older patients.

Sircana MC, Caturano A, Tettamanti M et al. · Internal and emergency medicine · (2026) · View on PubMed ↗

Macrophage PARP7 Alleviates Septic Cardiomyopathy by Interacting With TBK1 and Suppressing TBK1-Driven Inflammatory Response.

This mechanistic in vivo study tested whether macrophage PARP7 modulates septic cardiomyopathy by interacting with TBK1 and suppressing TBK1-driven inflammatory signaling in LPS-induced models. PARP7 deficiency worsened LPS-induced septic cardiomyopathy, while integrated single-nucleus and single-cell RNA sequencing showed PARP7 upregulation predominantly in cardiac macrophages. The work identifies a macrophage PARP7–TBK1 axis as a potential therapeutic target to reduce inflammatory toxicity in sepsis-associated heart failure.

Han J, Wang L, Zhong X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

---

Cardiovascular Disease & Stroke Prevention

Heart Failure and Cancer: Incidence and Mortality Patterns, A Systematic Review and Meta-analysis.

This systematic review and meta-analysis quantified how having heart failure (HF) affects subsequent cancer incidence and cancer-related mortality by synthesising observational studies and randomised trials comparing individuals with and without HF. The key finding was that HF was associated with distinct patterns of cancer incidence and mortality, indicating a clinically relevant bidirectional relationship between HF and cancer outcomes. The results are significant for risk stratification and for anticipating cardiotoxicity and cancer comorbidity in ageing populations and in patients receiving oncologic therapies.

Sanasi L, Iaconelli A, Azzolina D et al. · European journal of heart failure · (2026) · View on PubMed ↗

Comparative effectiveness of influenza vaccination dosing strategies for cardiovascular protection: a systematic review and network meta-analysis of randomised controlled trials.

This systematic review and network meta-analysis compared influenza vaccination dosing strategies—high-dose influenza vaccine (HD-IIV), double standard-dose, standard-dose (SD-IIV), and no vaccination—in adults with established cardiovascular disease using randomized controlled trials. The key finding was the relative effectiveness of different dosing strategies on trial-reported composite cardiovascular endpoints and related mortality outcomes via pairwise and network meta-analysis. This is important for cardiovascular secondary prevention because it helps determine which influenza vaccine dosing approach provides the best cardiovascular protection.

Hon JJ, Aikawa T, Biering-Sørensen T et al. · American heart journal · (2026) · View on PubMed ↗

Comparative efficacy and safety of rosuvastatin versus atorvastatin after acute ischemic stroke or transient ischemic attack: A systematic review and exploratory meta-analysis.

This systematic review and exploratory meta-analysis compared rosuvastatin versus atorvastatin for secondary prevention after acute ischemic stroke (AIS) or transient ischemic attack (TIA) using five included studies (one randomized trial and four cohort studies). The abstract truncation prevents extraction of the specific comparative efficacy and safety effect sizes, but the study’s aim was to determine which high-intensity statin is superior post-AIS/TIA. The clinical significance is that it informs guideline-consistent statin selection for stroke/TIA patients, where direct head-to-head evidence has been limited.

Cueva-Cañola LE, Beltran-De la Fuente AC, Ramírez Navarro DI et al. · Medicina clinica · (2026) · View on PubMed ↗

Vasoactive Agent Selection Strategies in the Management of Cardiogenic Shock.

This article reviewed and synthesized evidence on vasoactive agent selection strategies for patients with cardiogenic shock, focusing on pharmacologic profiles and comparative effectiveness data. The key finding is a strategic framework for choosing and titrating vasoactive drugs based on cardiogenic shock phenotypes to improve end-organ perfusion and blood pressure control. This is significant clinically because it translates pathophysiology and drug pharmacology into actionable bedside decision-making for a high-mortality condition.

Bohula EA, Morrow DA · Circulation · (2026) · View on PubMed ↗

---

Pulmonary Fibrosis & Lung Microenvironment

Deciphering the pulmonary fibrosis niche: A single-cell transcriptomic perspective on cellular crosstalk and microenvironment remodeling.

This review synthesized single-cell RNA sequencing and spatial transcriptomics evidence to describe the pulmonary fibrosis niche in idiopathic pulmonary fibrosis (IPF), emphasizing epithelial–mesenchymal–immune–endothelial ligand–receptor crosstalk and microenvironment remodeling. The key finding is that scRNA-seq/spatial approaches reveal a structured, actively communicating fibrotic niche rather than a simple sequence of epithelial injury followed by fibroblast activation. Scientifically, it reframes IPF pathogenesis as a multicompartment signaling network, supporting niche-targeted therapeutic strategies.

Deng R, Jiang S, Han X et al. · Cytokine & growth factor reviews · (2026) · View on PubMed ↗

---

Cancer Immunotherapy & Tumor Microenvironment (TME/TILs/biomarkers)

TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

In an exploratory cohort of 104 CAR T-cell recipients, the study examined whether pre-existing clonal hematopoiesis of indeterminate potential (CHIP) influences CAR-T toxicity and outcomes, focusing on TP53-mutant CHIP. Overall CHIP status was not broadly associated with inflammatory toxicities or systemic inflammation, but TP53-mutant CHIP defined a pro-inflammatory phenotype and predicted adverse outcomes after CAR T-cell therapy. This is clinically significant because it suggests TP53-mutant CHIP could be used for risk stratification and for anticipating inflammatory complications in CAR-T patients.

Rappa G, Ziemann F, White K et al. · Leukemia · (2026) · View on PubMed ↗

Multimodal spatial profiling reveals distinct myeloid-defined ENKTL subgroups and tumor-myeloid cooperativity within prognostic inflammatory niche.

This study analyzed extranodal NK/T-cell lymphoma (ENKTL) tumor microenvironments using integrated spatial transcriptomics, spatial proteomics, and single-cell spatial molecular imaging in patient ENKTL samples. It identified two macrophage-defined ENKTL subgroups—an inflammatory IFN-α/γ–responsive, IDO1/CD274-enriched subgroup and an immune-quiescent, macrophage-sparse subgroup skewed toward STAB1 macrophages—linked to distinct tumor–myeloid cooperativity in a prognostic inflammatory niche. These spatially resolved macrophage programs suggest biomarker-stratified microenvironment targeting strategies for EBV-associated ENKTL.

Deng L, Liu M, Linton REA et al. · Leukemia · (2026) · View on PubMed ↗

Cancer-associated adipocytes: metabolic reprogramming, crosstalk and therapeutic implications in tumor progression.

This review summarized evidence on cancer-associated adipocytes (CAAs) in the tumor microenvironment, focusing on their metabolic reprogramming, bidirectional crosstalk with other TME components, and therapeutic implications. It reports that CAAs lose large lipid droplets, adopt fibroblast-like features, intensify lipolysis, and release proinflammatory mediators and extracellular vesicles (including exosomal microRNAs) that promote proliferation, invasion, immune recruitment, ECM remodeling, and angiogenesis. The synthesis highlights CAAs as actionable metabolic and signaling targets to limit tumor progression and therapy resistance.

Shi J, Abdel-Ghany S, Abdel-Fattah M et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗

Cellular and molecular impacts of CELMoDs and IMiD on the induction of myeloid-derived suppressor cells by myeloma cells.

This study investigated how cereblon E3 ligase modulators (CELMoDs) and immunomodulatory drugs (IMiDs)—specifically iberdomide (IBER) and mezigdomide (MEZI)—affect the induction of monocytic myeloid-derived suppressor cells (M-MDSCs) in multiple myeloma. In PBMC–myeloma co-culture systems, CELMoDs altered molecular pathways (including IL-6/JAK-STAT3 signaling) that drive M-MDSC induction, and their effects were compared directly with pomalidomide (POM). These results identify immunomodulatory mechanisms beyond direct tumor killing that could help optimize MM therapies to reduce immunosuppressive MDSCs.

Niiyama-Uchibori Y, Tsukamoto T, Inoue Y et al. · British journal of haematology · (2026) · View on PubMed ↗

LARS2 reprograms mitochondrial metabolism and epigenetically upregulates MHC-I to boost antitumor immunity in nasopharyngeal carcinoma.

This study examined nasopharyngeal carcinoma (NPC) to determine how mitochondrial leucyl-transfer RNA synthetase 2 (LARS2) regulates tumor immunogenicity and antitumor immunity. It found that LARS2 reprograms mitochondrial metabolism and epigenetically upregulates MHC-I, increasing CD8+ T cell infiltration and improving antitumor responses in co-culture experiments and mouse models. These findings suggest LARS2–MHC-I axis modulation as a strategy to enhance immunotherapy efficacy in “hot” tumors with immune evasion.

Yang M, Mo Y, Ren D et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗

Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma.

This study validated the integrated 40-gene expression profile (i40-GEP) that combines a 40-GEP tumor biology test with five clinicopathologic features (including immunosuppression, location, differentiation, tumor diameter, and perineural invasion) to refine prognosis and adjuvant radiation benefit in high-risk cutaneous squamous cell carcinoma (HRcSCC). The key finding was that i40-GEP improved risk stratification and identified patients more likely to benefit from adjuvant radiation compared with clinicopathologic tools alone. This is significant because it supports more precise, biology-informed decisions to reduce under- or overtreatment in HRcSCC.

Ratner D, Singh G, Rizzo JM et al. · Journal of the American Academy of Dermatology · (2026) · View on PubMed ↗

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

This Review assessed evidence on tumour-infiltrating lymphocytes (TILs) as prognostic and predictive biomarkers in breast cancer, focusing on how TILs may influence response to breast radiotherapy. The key finding is that while high pre-treatment TILs consistently correlate with better outcomes and systemic-therapy response, clinical evidence for TIL-mediated radiotherapy benefit is still limited and mechanistic pathways remain incompletely defined. Standardised TIL reporting and integration of TIL endpoints into radiation oncology trials are needed to enable biomarker-driven individualisation of radiotherapy in breast cancer.

Gunster JLB, Tramm T, Machiels M et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

This independent validation study evaluated whether AI-derived tumour-infiltrating lymphocyte (TIL) scores predict outcomes in patients with triple-negative breast cancer, comparing AI quantification against pathologist-scored TILs using prospectively collected trial data. The key finding is that the CATALINA study was designed to test the prognostic performance of AI-derived TIL scores versus manual scoring across pooled randomized controlled trials, establishing whether AI TIL quantification can reproduce clinically meaningful prognostic signal. If validated, AI-based TIL scoring could improve efficiency and scalability of TIL biomarker assessment for risk stratification in triple-negative breast cancer.

Dixon-Douglas JR, Drubay D, Salgado R et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

This secondary analysis of the phase 3 APHINITY trial studied stromal TILs (sTILs) in 4805 patients with early-stage HER2-positive breast cancer treated with chemotherapy plus trastuzumab and either pertuzumab or placebo, using manual, digital, and AI-based sTIL quantification plus AI-derived spatial metrics. The key finding is that the study evaluated whether these different sTIL measurement modalities and spatial features can stratify prognosis and treatment benefit under dual HER2 blockade. Clinically, this supports refining how sTILs are measured (including spatial context) to better identify which patients may derive greater benefit from pertuzumab-containing regimens.

Lara González LE, Giudici F, Salgado R et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Convergent roles of GDF-15 in mechanotransduction, vascular disorganization, and immune suppression in melanoma.

This PNAS study examined how growth differentiation factor-15 (GDF-15) contributes to melanoma mechanotransduction, vascular disorganization, and immune suppression across melanoma types. The key finding is that GDF-15 is mechanically induced by extracellular matrix rigidity and compressive forces during metastatic progression, leading to elevated GDF-15 levels in both cutaneous and acral melanoma cells. Scientifically and clinically, it links tumor mechanics to immune-evasive biology and suggests GDF-15 as a mechanosensing-regulated therapeutic target in advanced melanoma.

Chen YC, Bollu VS, Kheirabadi S et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

Structural basis of GSDME pore formation and its regulation by S-palmitoylation.

The study determined the structural mechanism of gasdermin E (GSDME) pore formation and how S-palmitoylation regulates it in human cells. Using cryo-electron microscopy (cryo-EM), the authors resolved a 3.16 Å structure of the GSDME N-terminal pore showing a 28-subunit homo-oligomer and identified conformational features governing pore assembly and regulation by S-palmitoylation. This is significant because it provides a molecular basis for how posttranslational lipid modification controls pyroptosis, informing strategies to modulate chemotherapy-induced tissue damage and antitumor immunity.

Du G, Ehrmann JF, Lieberman J et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

SIRT2 deacylase modulators control B cell metabolic reprogramming in EBV infection and mitogenic activation.

The study evaluated whether SIRT2 deacylase modulators can control B cell metabolic reprogramming during Epstein–Barr virus (EBV) infection and mitogenic activation. The key finding is that targeting SIRT2 alters metabolic programs in B cells in EBV-driven contexts, supporting SIRT2 as a tractable node for viral-driven B cell dysfunction and activation. This is significant because it advances SIRT2-targeted therapeutic potential for EBV-associated malignancies by connecting a specific metabolic regulator to viral oncogenic biology.

Hill KK, Barry AP, Reinoso-Vizcaino NM et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

The study investigated whether T-cell immunosenescence limits the function of CD19 CAR T cells (CTL019) in chronic lymphocytic leukemia (CLL). It found that in response-linked preinfusion CTL019 products, nonresponders and short partial responders had higher immunosenescence features (including costimulatory loss, DNA damage, inflammatory secretion, repertoire restriction, and proliferative arrest) that correlated with impaired CAR T-cell performance. This is significant because it identifies immunosenescence as a mechanistic barrier to CAR T efficacy, suggesting that senescence-targeting strategies could improve outcomes in CLL.

Noll JH, Dersh D, Li JY et al. · Blood · (2026) · View on PubMed ↗

Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma.

The study explored T-cell receptor (TCR)-based targeting of intracellular antigens derived from immunoglobulin (Ig) heavy chain constant domains for multiple myeloma. Using HLA class I peptidomics, it identified nine IgG/IgA-derived peptides presented by common HLA alleles, isolated high-avidity T-cell clones from HLA-mismatched healthy donors, and demonstrated that transfer of these Ig-specific TCRs into donor T cells enabled recognition of myeloma-relevant targets. This is significant because it provides a strategy to broaden TCR-based immunotherapy beyond surface antigens and potentially reduce relapse driven by antigen escape in multiple myeloma.

Meeuwsen MH, Wouters AK, Wellershoff JC et al. · Blood · (2026) · View on PubMed ↗

---

Targeted Oncology (ADCs, TKIs, radioligand therapy, chemoradiotherapy)

Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.

This phase I/II multicohort study (Magic-C001; NCT05688605) evaluated the EGFR-directed antibody-drug conjugate becotatug vedotin (BV) combined with the PD-1 inhibitor pucotenlimab in patients with EGFR-positive recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) who had progressed after platinum and anti–PD-1/PD-L1 therapy. The key finding was that BV plus pucotenlimab produced clinically meaningful antitumour activity with an acceptable safety profile in this heavily pretreated, platinum- and immunotherapy-resistant population. Clinically, the results suggest a potential next-line regimen that couples EGFR-targeted cytotoxic delivery with PD-1 pathway blockade for R/M NPC after standard therapies fail.

Ruan DY, Wang FH, Zhou Y et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

Inhibition of nucleoporin 214 depletes leukemia stem cells by promoting heme catabolism and lipid peroxidation.

This study investigated how nucleoporin 214 (NUP214) regulates leukemia stem cell (LSC) survival in acute myeloid leukemia (AML), focusing on the consequences of NUP214 depletion on heme metabolism and oxidative stress pathways. The key finding was that inhibiting or depleting NUP214 promoted heme catabolism, increased Fe2+ accumulation, and triggered excessive lipid peroxidation, leading to LSC depletion via upregulation of HMOX1 and ALOX15. Scientifically, it identifies NUP214 as a mechanistic vulnerability in AML LSCs and supports targeting NUP214-associated metabolic/oxidative programs as a therapeutic strategy.

Chen Z, Wu F, Zhang W et al. · Blood · (2026) · View on PubMed ↗

PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.

Using domain-focused CRISPR screens across RNA-modifying enzymes and RNA-binding proteins, the authors identified dependencies in acute myeloid leukemia (AML), with particular attention to PTBP1 and RBM15, and validated findings in cancer cell models. They showed that PTBP1 controls oncogenic transcript processing and is a dependency—especially enriched in aggressive KMT2A-rearranged AML—linking PTBP1 function to malignant RNA regulation. This is significant because it nominates PTBP1 as a mechanistic vulnerability for targeted AML therapy, particularly in KMT2A-r disease.

Cao Z, McCannell KN, Yu S et al. · Leukemia · (2026) · View on PubMed ↗

Targeting CDKs in the RNAPII transcription cycle.

This Review synthesized evidence on cyclin-dependent kinases (CDKs) that regulate the RNA polymerase II (RNAPII) transcription cycle, covering initiation, elongation, termination, and related co-transcriptional processes in cancer and other diseases. It highlights that transcriptional/co-transcriptional CDKs have become promising therapeutic targets beyond classic cell-cycle CDKs, with dysregulation of transcriptional CDK control contributing to cancer gene-expression programs. Scientifically, it provides a mechanistic framework to guide next-generation CDK inhibitor discovery aimed at transcriptional vulnerabilities.

Fisher RP, Geyer M · Nature reviews. Drug discovery · (2026) · View on PubMed ↗

Circadian control of circulating tumour-derived extracellular vesicle secretion affects targeted therapy efficacy.

This study investigated how circadian timing of circulating tumor-derived extracellular vesicle (ctEV) secretion influences the efficacy of targeted therapy, using a tool called ctEV-CLOCK to isolate nascent ctEVs at 12-hour resolution. It found that ctEV abundance and functional properties oscillate with circadian dynamics, meaning the time of ctEV release affects downstream therapeutic responsiveness. These findings support chronotherapy-like strategies that schedule targeted treatments to match ctEV secretion phases for improved efficacy.

Chen M, Zhang Y, Zhu Y et al. · Nature cell biology · (2026) · View on PubMed ↗

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

This multicenter, open-label, single-arm phase IIb trial studied sutetinib, an irreversible EGFR tyrosine kinase inhibitor, in adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations (G719X, S768I, L861Q, or predefined compound mutations) and no prior EGFR-TKI therapy. The trial assessed sutetinib’s safety and antitumor efficacy as first-line treatment in this molecularly defined population. The results provide prospective evidence to guide first-line therapy selection for patients with uncommon EGFR-mutant NSCLC.

Wu F, Zhang W, Zhao Y et al. · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · (2026) · View on PubMed ↗

SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.

This multicentre, single-arm phase 1 trial evaluated SHR-A2102, a nectin-4–directed antibody-drug conjugate delivering a topoisomerase I inhibitor payload via a cleavable linker, in adults with pretreated advanced solid tumours. The key finding is that the study assessed safety, preliminary antitumour activity, and pharmacokinetics across dose-escalation and expansion cohorts using a Bayesian Optimal Interval design. Scientifically and clinically, targeting nectin-4 with a topoisomerase I payload aims to establish a therapeutic window and early efficacy signals for patients with advanced solid tumours after prior therapy.

Zhong R, Hong H, Yan M et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial.

This multicentre randomized phase 1b/2 trial studied ifebemtinib (a focal adhesion kinase inhibitor) combined with the KRASG12C inhibitor garsorasib in previously treated metastatic colorectal cancer harboring KRAS G12C mutations. The key finding is that the phase 1b component established the recommended phase 2 dose based on safety/tolerability (with no dose-limiting toxic effects reported in the provided excerpt) for the combination in KRASG12C-mutated solid tumours. The significance is that dual pathway inhibition (FAK signaling plus KRASG12C blockade) is being clinically tested to improve outcomes in a molecularly defined colorectal cancer population.

Song Z, Zhu L, Liu Y et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

CRB-701: a Second-Generation Nectin-4 Targeted Antibody-Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors.

This preclinical study developed and characterized CRB-701 (SYS6002), a second-generation nectin-4 targeted antibody-drug conjugate (ADC) for solid tumors. CRB-701 was engineered with microbial transglutaminase (mTGase) technology to conjugate two monomethyl auristatin E (MMAE) molecules via a cleavable linker to a high-affinity anti–nectin-4 monoclonal antibody, aiming for improved stability and pharmacokinetics compared with earlier constructs. By optimizing an established nectin-4 ADC platform, the work supports CRB-701 as a candidate for improved therapeutic index in nectin-4–expressing cancers.

Sun Z, Dan M, Lv L et al. · Cancer research communications · (2026) · View on PubMed ↗

Outcomes of [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study.

In a single-center retrospective cohort of 208 patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA-617 radioligand therapy, the study compared outcomes with concurrent enzalutamide versus no concurrent androgen receptor pathway inhibitor. Concurrent enzalutamide was associated with differences in key endpoints including overall survival (primary) and progression-free survival and response measures such as PSA50 (as evaluated in the real-world cohort). These findings inform how combining enzalutamide with PSMA-targeted radioligand therapy may affect effectiveness in mCRPC patients.

Arslan DF, Civan C, Sanli MO et al. · European journal of nuclear medicine and molecular imaging · (2026) · View on PubMed ↗

Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer-Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy.

This preclinical cancer immunotherapy study developed a Transformer-based framework (DLINP) to identify precision agonists that uncouple Type I interferon (IFN-I) induction from pro-inflammatory toxicity, then tested the top candidate Co68 in pancreatic ductal adenocarcinoma (PDAC) models. Co68 produced potent antitumor responses with improved safety by separating IFN-I benefits from inflammatory toxicity compared with conventional taxanes like paclitaxel. The approach provides a rational platform for designing safer immunomodulatory agents and highlights Co68 as a candidate for next-step development in PDAC immunotherapy.

Guo X, Zhao Y, Rong X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

---

Clinical Trials in Oncology (phase 1–3 outcomes, QoL, regimen comparisons)

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.

This multicentre, randomised, open-label phase 3 trial studied whether adding atezolizumab plus bevacizumab to on-demand transarterial chemoembolisation (TACE) improves outcomes in systemically untreated, unresectable intermediate-to-high tumour burden hepatocellular carcinoma (HCC) patients in China and Japan. The key finding was that the combination strategy outperformed on-demand TACE alone in the trial’s prespecified efficacy endpoints (including failure-free survival/relapse-related outcomes as reported in the abstract’s results section). If confirmed in full reporting, TALENTACE would support a new standard of care by integrating PD-L1 blockade (atezolizumab) and VEGF inhibition (bevacizumab) with TACE for intermediate-stage HCC.

Kudo M, Ogasawara S, Liu R et al. · The lancet. Gastroenterology & hepatology · (2026) · View on PubMed ↗

Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma.

This multicentre randomised trial studied induction chemotherapy with paclitaxel–cisplatin–capecitabine (TPC) versus cisplatin–fluorouracil (PF) in high-risk locally advanced nasopharyngeal carcinoma (LA-NPC), followed by concurrent chemoradiotherapy. The key finding was that the TPC induction regimen maintained superior 5-year failure-free survival (FFS) compared with PF, with prespecified secondary outcomes reported as consistent with the earlier signal. This supports TPC as an evidence-based induction approach to improve long-term disease control in high-risk LA-NPC.

Li WZ, Lv SH, He SQ et al. · NEJM evidence · (2026) · View on PubMed ↗

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.

This prospective phase II multicentre study tested whether mutation clearance in acute myeloid leukemia (AML) during first complete remission (CR1) can guide consolidation therapy, comparing outcomes in intermediate-risk, transplant-eligible de novo AML patients who achieved CR/CRi after induction. The key finding was that patients with clearance of leukemia-associated mutations (LAMs) had lower relapse risk and better outcomes, supporting the concept that molecular response can inform consolidation intensity (including high-dose cytarabine use). Scientifically and clinically, it advances mutation-guided consolidation as a strategy to personalise therapy in intermediate-risk AML.

Jacoby MA, Spencer DH, Gao F et al. · NEJM evidence · (2026) · View on PubMed ↗

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

In transplant-ineligible newly diagnosed multiple myeloma, the MAIA trial’s long-term follow-up assessed daratumumab plus lenalidomide/dexamethasone (D-Rd) versus lenalidomide/dexamethasone (Rd) in 737 randomized patients. At a median follow-up of 89.3 months, D-Rd maintained an overall survival benefit compared with Rd, with subsequent therapy outcomes also characterized. This is clinically significant because it confirms durable survival advantage for D-Rd in a key real-world treatment population.

Facon T, Kumar SK, Orlowski RZ et al. · Leukemia · (2026) · View on PubMed ↗

Chronic liver disease is associated with earlier-stage cholangiocarcinoma diagnosis and improved prognosis: Findings from the GLOBAL-BTC registry.

This retrospective GLOBAL-BTC registry analysis studied whether chronic liver disease (CLD)—defined by primary sclerosing cholangitis, cirrhosis, viral hepatitis, or other chronic liver disorders—affects clinical presentation and outcomes in 3,743 patients with cholangiocarcinoma (CCA) diagnosed from 2010–2024. Patients with CLD were associated with earlier-stage CCA diagnosis and improved prognosis compared with those without CLD. The findings are important for risk stratification and clinical management of CCA by suggesting that CLD status may influence stage at detection and survival.

Izquierdo-Sanchez L, Narbaiza J, Martin-Robles J et al. · Journal of hepatology · (2026) · View on PubMed ↗

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

This report updated results from the phase III OlympiA trial (NCT02032823) evaluating 1 year of adjuvant olaparib, a PARP inhibitor, versus placebo in 1,836 women with germline BRCA1/BRCA2 pathogenic/likely pathogenic variants and high-risk HER2-negative early breast cancer. The key finding was sustained benefit with olaparib, with continued improvements in invasive disease-free survival, distant disease-free survival, and overall survival in the updated analysis. Clinically, this supports long-term use of adjuvant olaparib to reduce recurrence and improve survival in gBRCA-associated high-risk early breast cancer.

Garber JE, Cameron D, Campbell C et al. · Annals of oncology : official journal of the European Society for Medical Oncology · (2026) · View on PubMed ↗

High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.

This randomized phase 3 trial (GETUG AFU 18) studied whether dose-escalated external-beam radiotherapy (80 Gy vs 70 Gy) improves progression-free survival in men with high-risk prostate cancer receiving long-term androgen deprivation therapy (ADT). The key finding is that the trial tested the effect of a 10 Gy increase on progression-free survival in a high-risk population defined by PSA ≥20 ng/mL, Gleason score ≥8, or clinical stage T3–T4. The results address whether radiotherapy dose escalation adds survival benefit beyond ADT in high-risk prostate cancer, informing optimal radiotherapy dosing strategies.

Hennequin C, Sargos P, Roca L et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.

This randomized open-label phase 3 trial (ALINA) assessed health-related quality of life (HRQoL) and safety outcomes in patients with resected ALK-positive non-small-cell lung cancer receiving adjuvant alectinib versus platinum-based chemotherapy. The key finding is that the study reports safety and HRQoL endpoints alongside the previously established disease-free survival benefit of adjuvant alectinib in this setting. Clinically, these outcomes determine whether improved efficacy with alectinib is accompanied by acceptable tolerability and patient-reported quality-of-life impact after surgery.

Dziadziuszko R, Ahn JS, Barlesi F et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

This multicentre randomized double-blind phase 3 trial (HARMONi) studied ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-squamous NSCLC whose disease progressed after third-generation EGFR TKI therapy. The key finding is that the trial was designed to evaluate efficacy and safety of adding ivonescimab in this post–third-generation TKI progression population. The significance is that it tests whether an antibody-based strategy can improve outcomes beyond standard chemotherapy after resistance to third-generation EGFR TKIs.

Le X, Passaro A, Zhao Y et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.

This global randomized open-label sponsor-blinded phase 3 study (EMERALD-3) evaluated durvalumab plus tremelimumab (STRIDE), with or without lenvatinib, combined with transarterial chemoembolisation (TACE) in participants with embolisation-eligible hepatocellular carcinoma (HCC). The key finding is that the trial specifically tests whether adding STRIDE and optionally lenvatinib to TACE improves efficacy and maintains acceptable safety in this standard-of-care–adjacent setting. Scientifically and clinically, it targets the hypothesis that TACE-induced immune responses can be amplified by checkpoint blockade (and VEGF inhibition via lenvatinib) to improve HCC outcomes.

Kudo M, Abou-Alfa GK, Ren Z et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.

This randomized phase 3 trial studied daily low-dose carboplatin versus weekly carboplatin plus nab-paclitaxel in patients aged ≥75 years with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent thoracic radiotherapy, with durvalumab maintenance recommended afterward. The key finding is not fully available in the truncated abstract, but the trial was designed to test non-inferiority of weekly carboplatin plus nab-paclitaxel for overall survival compared with daily carboplatin. Clinically, results from JCOG1914 are intended to guide optimal chemoradiotherapy regimen selection for older, unresectable LA-NSCLC patients.

Omori S, Kenmotsu H, Nomura S et al. · Lung cancer (Amsterdam, Netherlands) · (2026) · View on PubMed ↗

---

Neurodegeneration & Proteinopathies (AD/α-synuclein/TDP-43)

Distinct Filament Conformation for Receptor-Bound Amyloid-β from Alzheimer’s Disease Brain.

This study isolated a receptor-bound amyloid-β (Aβ) pool from Alzheimer’s disease brain using release with a receptor antagonist followed by purification to homogeneity. It found that the receptor-bound Aβ species is ~10-fold more abundant than free unbound Aβ and consists of ~65 nm long filaments whose tips bind prion protein and drive synapse loss in human neuronal tissue. These results pinpoint a specific receptor-bound Aβ filament conformation as a likely mechanistic driver of synaptic pathology.

Kostylev MA, Butan C, Roseman GP et al. · Nature communications · (2026) · View on PubMed ↗

Presymptomatic plasma biomarkers in autosomal dominant Alzheimer’s disease: sequence and timing.

This longitudinal cohort study evaluated presymptomatic plasma proteomic biomarkers in autosomal dominant Alzheimer’s disease (ADAD), comparing 73 mutation carriers versus 40 non-carriers using a 124-protein NUcleic acid-Linked Immuno-Sandwich Assay panel across 270 plasma samples. It identified sequence- and timing-dependent plasma proteomic changes that distinguish mutation carriers from non-carriers and map biomarker trajectories relative to predicted age at symptom onset. These results improve interpretation of presymptomatic biomarker dynamics and can inform the design and timing of future ADAD clinical trials.

Belder CRS, Heslegrave AJ, Swann O et al. · Journal of neurology, neurosurgery, and psychiatry · (2026) · View on PubMed ↗

Splicing modulation of ATXN2 as a therapeutic strategy to regulate Ataxin-2 protein levels in ALS.

The study investigated whether splicing modulation of ATXN2 could lower Ataxin-2 protein levels in rNLS8 mice, a model in which doxycycline withdrawal increases Ataxin-2 alongside TDP-43 overexpression, phosphorylation, and aggregation. Bioinformatic analysis identified an alternative 5’ splice site in ATXN2 intron 8 that adds 47 bp after exon 8, and the authors explored this splicing change as an RNA-level therapeutic strategy to reduce Ataxin-2. This work is significant because it links ATXN2 splicing control to downstream TDP-43 pathology, offering a gene-targeted approach for ALS beyond simple ATXN2 downregulation.

Heinsinger N, Wang Y, Grauer S et al. · Neurobiology of disease · (2026) · View on PubMed ↗

Cholesterol dysregulation in APOE4 astrocytes promotes α-synuclein pathology in miBrains.

This study used an iPSC-based 3D human brain-like tissue model (“miBrain”) containing neurons, glia, myelin, and cerebrovascular cells to test how cholesterol dysregulation in APOE4 astrocytes affects α-synuclein pathology. The key finding is that single-nucleus RNA sequencing confirmed diverse cell populations in miBrains and revealed transcriptional responses to α-synuclein pathology, linking APOE4 astrocyte cholesterol dysregulation to downstream α-synuclein disease processes. The significance is that this human-relevant model enables mechanistic dissection of APOE4-driven neurodegeneration pathways, supporting target discovery for α-synuclein–related disorders.

Mesentier-Louro LA, Goldman C, Gaese S et al. · Cell stem cell · (2026) · View on PubMed ↗

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.

This JAMA Neurology review conceptualized and proposed integrated staging for transactive response DNA-binding protein 43 kDa (TDP-43)–associated neurodegenerative disease across multiple clinical syndromes. It emphasized that TDP-43 pathology is shared across disorders such as limbic predominant age-related encephalopathy (LATE), most ALS, inclusion body myositis, multisystem proteinopathy, and about half of frontotemporal dementia (FTD), arguing for classification by underlying pathobiology rather than phenotype. This framework is significant because it can improve biomarker development and therapy targeting by aligning clinical trials with a common molecular substrate.

Benatar M, Barmada S, Jicha GA et al. · JAMA neurology · (2026) · View on PubMed ↗

Entorhinal Astrocyte Transplants Restore Spatial Exploration and Alleviate Amyloid-Beta Pathology in Alzheimer’s Mice.

In APP/PS1 Alzheimer’s mouse models, this study examined whether entorhinal astrocyte transplants could restore spatial exploration and reduce amyloid-beta pathology. Transplanted glial progenitor cells differentiated into homeostatic astrocytes, restored perivascular Aquaporin-4 polarization, reduced amyloid-beta burden, attenuated neuroinflammation, and preserved synaptic integrity. These findings support astrocyte replacement/remodeling in the medial entorhinal cortex as a strategy to improve cognition-relevant behavior and disease pathology in AD.

Wu F, Fan J, Zhou X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

---

Neurodevelopmental & Genetic Mechanisms (rare variants, epigenetics, syndromes)

Intraosseous calvarial haematoma mimicking a skull tumour in a child with Noonan syndrome: a case report.

This case report described a 14-year-old female with Noonan syndrome who developed intraosseous calvarial lesions that mimicked a skull tumour clinically and radiologically. The key finding was that surgical excision with histopathology confirmed intraosseous calvarial haematoma rather than neoplasia, despite imaging features suggesting malignancy. The report is significant because it expands the differential diagnosis of skull lesions in Noonan syndrome and highlights the potential for substantial intraoperative bleeding.

Ibrahim B, Al-Dabbas W, Awad M et al. · Journal of surgical case reports · (2026) · View on PubMed ↗

JP1 peptide modulates oxidative stress and autophagy via Keap1-Nrf2-ARE in ALS model mice.

JP1, an engineered oligopeptide derived from the stress-responsive protein JWA, was tested in ALS model mice to determine how it modulates oxidative stress and autophagy through the Keap1–Nrf2–ARE pathway. JP1 promoted coordinated regulation of redox homeostasis and autophagy by engaging Keap1-Nrf2-ARE signaling, linking neuroprotective effects to downstream stress-response mechanisms. These results are scientifically significant because they support JP1 as a candidate strategy for ALS that simultaneously targets oxidative stress and autophagic dysregulation.

Zhang Y, Liu Y, Shi S et al. · BMC medicine · (2026) · View on PubMed ↗

The clinical and molecular spectrum of AGO2-associated Lessel-Kreienkamp neurodevelopmental syndrome.

The study characterized the clinical and molecular spectrum of AGO2-associated Lessel-Kreienkamp neurodevelopmental syndrome in 45 newly identified individuals carrying 33 AGO2 variants, integrating them with previously reported cases (total n=70) and performing functional assays. Using shRNA-based silencing and co-immunoprecipitation/co-immun studies, the authors mapped genotype–phenotype relationships and clarified how distinct AGO2 variants disrupt RNA-induced silencing complex (RISC) function. This is significant for precision diagnosis and for understanding how specific AGO2 molecular defects drive variable disease severity in LESKRES.

Tibbe D, Kiel C, Ielesicheva O et al. · Genome medicine · (2026) · View on PubMed ↗

Cohesin acts as a transcriptional gatekeeper by restraining pause-release to promote processive elongation.

This study investigated how cohesin regulates transcription in human cells by analyzing its roles in RNA polymerase II (Pol II) promoter recruitment and pause-release kinetics. It found that cohesin both promotes Pol II recruitment via promoter–enhancer communication that maintains active promoter chromatin states and delays pause release through transient association during the pause-release transition. By explaining why cohesin loss can yield minimal steady-state gene-expression changes, it identifies transcriptional gating as a key function of cohesin.

Tei S, Bando M, Sakata T et al. · Nature communications · (2026) · View on PubMed ↗

Multi-subunit collaboration enables Smc5/6 to function as a composite SUMO E3 complex.

This study investigated how the Smc5/6 genome-protecting complex functions as a composite SUMO E3 ligase in budding yeast, using biochemical SUMOylation assays and cellular SUMOylation readouts. It showed that DNA stimulates Smc5/6 E3 activity by fostering proximity between enzyme and substrate, and that four non-SUMO E3 subunits cooperate to enable Smc5/6’s SUMOylation function. These findings clarify the multi-subunit architecture of Smc5/6 as a SUMO E3 complex, informing how genome protection is regulated through SUMOylation.

Xue X, Fan J, Li S et al. · Nature communications · (2026) · View on PubMed ↗

Dysregulated differentiation kinetics underlie the essential role of DNA damage repair in placental development.

This study used single-nucleus multi-omics profiling to characterize placental development in somatic cell nuclear transfer (SCNT) models, focusing on trophoblast differentiation and DNA damage repair programs. SCNT placentas showed dysregulated differentiation kinetics, including persistent multipotency of arrested trophoblast precursors, an aberrant junctional zone trajectory, impaired VEGF signaling, and mechanistic links to defective DNA damage repair. These findings suggest that DNA damage repair is essential for correct trophoblast differentiation timing and vascular development, providing a mechanistic framework for SCNT placental pathology and potential targets to improve placental function.

Yi S, Wang M, Zhu Q et al. · Nature communications · (2026) · View on PubMed ↗

An inherited hypomorphic variant in PIEZO2 reveals structural features of mechanotransduction.

This study investigated a novel PIEZO2 missense variant (N2434K) in fraternal twins with proprioceptive ataxia and scoliosis, using gene-edited mice and in vivo sensory neuron mechanical recordings. The N2434K variant, in compound heterozygosity with a null allele, produced severely reduced mechanically evoked currents despite normal membrane expression, consistent with defective PIEZO2 gating. These findings define a structural mechanotransduction feature of PIEZO2 and provide a mechanistic explanation for human proprioceptive failure due to hypomorphic PIEZO2 function.

Nickolls AR, Mulhall EM, Orlin DJ et al. · Neuron · (2026) · View on PubMed ↗

DDIAS shields single-stranded DNA in mitosis and promotes vertebrate brain development.

This study identified DDIAS as a mitosis-specific DNA damage response protein and examined its role in the TOPBP1–CIP2A pathway, focusing on protection of single-stranded DNA during chromosome segregation in human cells. DDIAS was shown to be a phosphorylation-dependent effector of the TOPBP1–CIP2A complex that shields ssDNA from aberrant nucleolytic processing to preserve chromosome integrity, with particular relevance to BRCA1/BRCA2-deficient contexts. Clinically, this links a mitotic genome-maintenance mechanism to synthetic-lethal vulnerabilities and suggests why HR-deficient tumors may depend on DDIAS-mediated ssDNA protection.

Tsukada K, Lototska L, Tsukada A et al. · Cell · (2026) · View on PubMed ↗

Mitotic single-stranded DNA suppression by DDIAS.

This study characterized DDIAS as a DNA-binding effector of the CIP2A pathway in human cells, using protein interaction assays and functional genetics to test dependence on BRCA1/BRCA2 status. DDIAS physically interacts with TOPBP1, and its inactivation causes synthetic lethality with BRCA1 and BRCA2 deficiency, while HR-deficient tumors upregulate DDIAS to tolerate genomic instability. The work positions DDIAS–TOPBP1 ssDNA repair/maintenance as a potential therapeutic target in HR-deficient cancers.

Xue Y, Rashed FB, Mao DYL et al. · Molecular cell · (2026) · View on PubMed ↗

The R-loop-SPT6-SETD2 axis safeguards H3K36me3 to prevent broad H3K4me3 invasion in mouse oocytes.

This study investigated how R-loops regulate histone crosstalk during mouse oocyte maturation, focusing on the R-loop resolution factor RNASEH1 and the R-loop–SPT6–SETD2 pathway controlling H3K36me3 and H3K4me3. Resolving R-loops with RNASEH1 reduced SETD2-dependent H3K36me3 in oocyte gene bodies, which triggered broad H3K4me3 invasion into H3K36me3-marked regions and repressed oocyte gene expression, with developmental potential compromised. The work links RNA–DNA structures to epigenetic barrier formation in germinal vesicle oocytes, highlighting RNASEH1/R-loop–SETD2 as a mechanistic axis for maintaining correct histone modification landscapes.

Sheng Y, Guo T, Ma Y et al. · Cell reports · (2026) · View on PubMed ↗

---

Neural Circuitry & Systems Neuroscience

Motor neurons organize Drosophila feeding sequences via a disinhibitory cascade.

In Drosophila performing feeding behavior, the authors used simultaneous quadruple-electrode recordings to determine how motor neurons organize feeding sequences via a disinhibitory cascade. They found that a leading motor neuron releases glutamate to excite its target muscle and disinhibit a premotor neuron, recruiting the next motor neuron in a millisecond-precision propagating feedforward wave. This is significant because it reveals a circuit mechanism for sequential motor control that can inform how disinhibition shapes behavior in neural systems.

Sui XW, Yi JJ, Zhou Y et al. · Nature neuroscience · (2026) · View on PubMed ↗

---

Autoimmunity & Immune Signaling (IFN, RNA surveillance, neuroimmunology)

Association of Demographic, Clinical, and Environmental Factors With Disease Severity in Adult Myasthenia Gravis: A Multicenter Cross-Sectional Study.

This multicentre cross-sectional study analysed adult patients in a national myasthenia gravis (MG) database to identify demographic, clinical, and environmental factors associated with disease severity. The key finding was that specific patient characteristics and environmental/socioeconomic/lifestyle variables correlated with MG severity as classified by MG Activities of Daily Living (MG-AD). Scientifically, it highlights modifiable and non-modifiable determinants of heterogeneity in MG severity and can inform risk stratification and future prospective studies.

Liu H, Wang J, Zhu W et al. · CNS neuroscience & therapeutics · (2026) · View on PubMed ↗

Evaluation of nailfold videocapillaroscopy findings in juvenile idiopathic arthritis.

This prospective cross-sectional study assessed nailfold videocapillaroscopy (NVC) findings in children with juvenile idiopathic arthritis (JIA) using the EULAR microcirculation protocol and compared results across JIA subtypes and with disease activity. The study evaluated microvascular abnormalities captured by NVC and related them to JIA subtype and activity status. The significance lies in establishing NVC as a potential noninvasive biomarker to characterize vascular involvement and monitor inflammatory activity in pediatric rheumatology.

Kucuk E, Ozdemir UF, Aydin Z et al. · Microvascular research · (2026) · View on PubMed ↗

MOGAD-Like Encephalitic Syndromes Without MOG Antibodies in Children.

This prospective cohort study examined children (<18 years) with encephalitis meeting MOGAD clinical–radiologic criteria but lacking MOG antibodies, using live cell-based assays (CBA-IIF and CBA-FACS) on serum (and CSF when available). The key finding is the frequency and characterization of MOGAD-like encephalitic syndromes occurring without MOG-IgG antibodies, along with their clinico-radiologic features and outcomes. This is significant for pediatric neuroimmunology because it refines diagnostic interpretation of MOGAD criteria and informs prognosis and antibody testing strategies.

Olivé-Cirera G, Fonseca EG, Guasp M et al. · Neurology(R) neuroimmunology & neuroinflammation · (2026) · View on PubMed ↗

Loss of epitranscriptomic mitochondrial RNA surveillance drives epithelial type I interferon and inflammation in autoimmunity.

This study investigated how loss of epitranscriptomic mitochondrial RNA surveillance promotes epithelial type I interferon and inflammation in autoimmunity, focusing on the RNA methyltransferase METTL3 and its regulation of REXO2 mRNA via m6A in primary salivary gland epithelial cells. The key finding is that METTL3 stabilizes REXO2 mRNA through N6-methyladenosine, and disruption of this regulatory axis drives mt-dsRNA–linked IFN-I activation and inflammatory signaling. This is significant because it provides a mechanistic, epithelial-intrinsic explanation for chronic interferon dysregulation in autoimmune disease and identifies METTL3/REXO2 as candidate intervention points.

Arco-Hierves A, Pamboukas K, Bilonda Mutala L et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

---

Microbiome, Gut Barrier & Metabolite Signaling

Enterochromaffin cells as a cellular integration hub for cooperative microbial signaling to modulate gut serotonin and motility.

The study investigated how enterochromaffin (EC) cells integrate microbial metabolite signals to control gut serotonin release and gastrointestinal motility, focusing on hypoxanthine and butyrate. It found that hypoxanthine activates the adenosine A1 receptor–TRPC4 axis in EC cells to drive calcium influx and serotonin release that accelerates local transit and increases systemic platelet activation, while butyrate conditions host responsiveness. This is clinically and scientifically significant because it links specific microbial metabolites to defined EC signaling pathways that regulate motility and systemic inflammatory/platelet effects.

Xiao Y, Louwies T, Mars RAT et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

Borrelia burgdorferi disrupts gut barrier functions and microbiota-antibody interactions.

This study investigated how Borrelia burgdorferi infection affects gut barrier function and microbiota–antibody interactions in mice and compared related blood changes in patients with acute Lyme disease. B. burgdorferi rapidly induced a “leaky gut” phenotype with increased gut permeability, systemic endotoxemia, and altered leukocyte profiles, and similar patient blood changes correlated with symptoms and liver function and largely resolved after antibiotics. The results link Lyme disease pathophysiology to gut barrier disruption and immune–microbiome interactions, suggesting potential biomarkers or adjunctive targets beyond antibiotics.

Sachan S, Tran GVV, Olsen KJ et al. · The Journal of experimental medicine · (2026) · View on PubMed ↗

---

Infectious Disease Mechanisms & Vaccines

Candida auris uses nutrient sensing to modulate virulence and host immune responses.

Candida auris was studied to determine how nutrient sensing alters virulence and host immune responses under different carbon sources, using experimental conditions modeling glucose-rich (blood-relevant) versus non-fermentable carbon sources (skin-relevant). The authors found that glucose-rich conditions suppress virulence traits and reduce immune detection, whereas non-fermentable carbon sources activate adhesion/filamentation and trigger macrophage responses. This is significant because it links environmental nutrient availability to immune evasion and pathogenicity, suggesting potential intervention points for C. auris.

Tedja I, Weerasinghe H, Bryak G et al. · Nature microbiology · (2026) · View on PubMed ↗

A dual-receptor checkpoint primes enterovirus D68 for respiratory cell entry.

This structural study investigated enterovirus D68 (EV-D68) entry into respiratory cells by characterizing the role of the newly identified receptor MFSD6, using near-atomic-resolution cryo-electron microscopy of AFM-associated viral strains and their complexes with the MFSD6 third extracellular loop (MFSD6-L3). It revealed a “binary gating switch” mechanism of virus–receptor engagement, including insertion of the MFSD6 N200–V208 segment containing glycosylated Asn207, that differs from previously proposed models. These findings provide a molecular basis for receptor-targeted interventions to block EV-D68 respiratory cell entry.

Liang S, Guo H, Xu Z et al. · Nature communications · (2026) · View on PubMed ↗

Arrestins as programmable integrators of GPCR signaling: structural microstates, spatiotemporal logic, and therapeutic control.

This review synthesized structural and mechanistic evidence on arrestins as programmable integrators of GPCR signaling, drawing on cryo-electron microscopy studies across GPCR classes and arrestin isoforms. It found that arrestin recruitment is conditional and allosterically regulated, with multiple engagement microstates (core-, tail-, loop-, side-engaged, and membrane-anchored) rather than a binary on/off switch. This mechanistic framework supports therapeutic strategies that control specific arrestin microstates and spatiotemporal signaling outputs.

He Q, Zhao LH, Xu HE · Cell discovery · (2026) · View on PubMed ↗

Zymosan-adjuvanted intranasal norovirus virus-like particle vaccine induces antiviral mucosal immune responses in infant mice.

The study evaluated an intranasal norovirus virus-like particle (VLP) vaccine adjuvanted with zymosan in an infant murine model to address weaker mucosal immunity after injectable vaccination. VLPs alone induced mucosal and systemic VLP-specific immune responses in infant mice that were substantially weaker than in adults, while the zymosan-adjuvanted intranasal strategy was tested to enhance these responses. This is clinically relevant because it supports development of pain-free, mucosally delivered vaccines optimized for immunologically immature infants.

Tsuchihashi T, Kurokawa S, Tamiya S et al. · Mucosal immunology · (2026) · View on PubMed ↗

A divergent mitochondrial cytochrome c in malaria parasites with an anomalously low redox potential.

The research characterized a divergent mitochondrial cytochrome c homolog in Apicomplexa, focusing on Plasmodium falciparum cytochrome c-2 (Pfcyt c-2) with anomalously low redox potential and heterogeneous heme coordination. The key finding was that Pfcyt c-2 retains His/Met axial ligands yet exhibits unusual heme coordination and a markedly low redox potential compared with canonical eukaryotic cytochrome c. This is scientifically significant because it reveals a lineage-specific electron-transfer adaptation in malaria parasites that could inform targeted disruption of parasite mitochondrial respiration.

Loveridge KM, Olsen OD, Scherer SR et al. · Journal of molecular biology · (2026) · View on PubMed ↗

Histone modification cross talk between a host and pathogen.

The study examined how the Legionella pneumophila histone lysine methyltransferases RomA and its homolog LegAs4 act in the context of the host epigenetic landscape during infection. The key finding is that RomA-mediated suppression of host immune responses via H3K14 methylation is constrained by preexisting host chromatin/epigenetic state, revealing host–pathogen histone modification cross talk that limits effector activity. This mechanistic insight is significant because it identifies host epigenetic context as a determinant of bacterial immune evasion and intracellular replication, suggesting new targets to modulate infection.

Miller SS, Hrit JA, Rothbart SB et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

---

Metabolism, Diet & Cardiometabolic Risk

Metformin in High Metabolic Risk Pregnancies - A Patient-Level Meta-Analysis.

This patient-level meta-analysis of double-blind, randomised placebo-controlled trials studied whether metformin given during pregnancy without preexisting diabetes prevents gestational diabetes mellitus (GDM) and adverse maternal and neonatal outcomes. The key finding was that metformin reduced the risk of GDM and improved some glycaemic outcomes on oral glucose tolerance testing, with effects on neonatal outcomes assessed across trials using individual participant data. Clinically, it strengthens the evidence base for considering metformin in pregnancies at high metabolic risk to prevent GDM and potentially improve pregnancy outcomes.

Mousa A, Løvvik TS, Carlsen SM et al. · NEJM evidence · (2026) · View on PubMed ↗

Estimating the risk of acute malnutrition among under-five children in Uganda: a distributional analysis of socioeconomic and structural inequalities.

This secondary analysis used a distributional epidemiology framework to estimate socioeconomic and structural inequality in acute malnutrition among under-five children in Uganda, using a nationally representative cross-sectional household survey from 2019/2020. It quantified how acute undernutrition risk is unevenly distributed across regions (Central, Eastern, Northern, Western) and across socioeconomic/structural strata, and assessed outcome-specific (aetiological) differences across nutritional endpoints. The study highlights equity-relevant targets for interventions rather than relying on national averages that can obscure high-risk subpopulations.

Robert Maurice M, Sam O · BMJ paediatrics open · (2026) · View on PubMed ↗

Liberal fruit and vegetable intake in patients with advanced CKD with or without Sodium zirconium cyclosilicate.

This randomized, crossover, non-inferiority trial studied whether a potassium-rich diet (achieved by adding ~40 mmol/day via extra fruits and vegetables) is feasible and safe in 16 advanced CKD patients receiving RAAS inhibitors, with or without sodium zirconium cyclosilicate (SZC) to mitigate hyperkalemia risk. The key finding was the ability to support a more liberal potassium intake in this population while maintaining safety constraints relevant to hyperkalemia. This is clinically significant because it tests whether potassium-binder–enabled dietary changes can deliver cardiorenal benefits in CKD patients who otherwise cannot tolerate high-potassium diets.

Moest WT, Snoeker B, Mallat MJK et al. · Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · (2026) · View on PubMed ↗

Gut microbiome-metabolome interactions during varied low-carbohydrate food consumption.

This randomized cross-over study in canines (n=35) tested how low-carbohydrate diets with carbohydrate replacement by fat versus protein affect gut microbiome–metabolome interactions, using fecal shotgun metagenomics/metatranscriptomics and blood/fecal metabolomics. The abstract truncation prevents reporting the specific direction and magnitude of the observed associations, but the study’s core finding is that diet composition strongly reshapes microbiome activity and host metabolite profiles. Scientifically, it clarifies biochemical pathways linking low-carbohydrate intake to metabolic and inflammatory outcomes and helps identify whether fat- or protein-based replacement drives different host responses.

Nearing JT, Kuntz T, Perdomo V et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study.

The study assessed associations between common antidiabetic medication regimens and the incidence of cognitive disorders in adults with type 2 diabetes using a retrospective cohort design. In TriNetX US electronic health records (2010–2024) with propensity score matching, it compared metformin-only users with combinations including DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors (among other groups). This is significant because it provides comparative real-world evidence on whether specific diabetes drug classes influence risk of mild cognitive disorder, Alzheimer disease, and vascular dementia.

Nasir AB, Kilani Y, Aldiabat M et al. · PloS one · (2026) · View on PubMed ↗

Prenatal Organophosphate Exposure and Autism-Related Traits in Children.

This pooled prospective cohort study assessed whether prenatal exposure to organophosphate (OP) pesticides is associated with autism-related traits in children, using harmonized mother-child data from 20 sites in the ECHO cohort. The analysis evaluated associations by child sex and maternal diet, addressing inconsistencies in prior literature linking prenatal OP exposure to ASD and related phenotypes. If confirmed, the findings would clarify environmental risk factors for autism-related outcomes and could inform dietary or exposure-reduction strategies during pregnancy.

Cavalier HM, Volk HE, Kivumbi A et al. · JAMA pediatrics · (2026) · View on PubMed ↗

---

Pharmacogenomics, Drug Safety & Precision Medicine

ALG-020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug-Induced Liver Injury.

ALG-020572, an antisense oligonucleotide targeting HBV mRNA to reduce viral protein synthesis, was evaluated in a double-blind, randomized, placebo-controlled trial (ALG-020572-401) in healthy participants and in non-cirrhotic HBeAg-negative, virologically suppressed adults with chronic hepatitis B. The study was discontinued due to drug-induced liver injury, establishing a key safety signal for this HBV mRNA–degrading approach. This finding is clinically significant because it limits further development of ALG-020572 despite the unmet need for therapies that suppress HBsAg in chronic HBV.

Agarwal K, Forton D, Zen Y et al. · Journal of viral hepatitis · (2026) · View on PubMed ↗

PFAS: challenges and scientific perspectives in human health risk assessment.

This article reviewed current scientific advances and challenges for per- and polyfluoroalkyl substances (PFAS) human health risk assessment, drawing on discussions from an International PFAS Conference organized by the German Federal Institute for Risk Assessment (BfR) and building on EFSA’s 2020 opinion. It highlighted key priorities across analytical methods, human exposure, toxicokinetics, and toxicity to improve risk assessment for the >21,000 PFAS in use. The significance lies in guiding regulatory and research next steps to strengthen consumer health protection despite major data and methodological gaps.

Kowalczyk J, Abraham K, August C et al. · Archives of toxicology · (2026) · View on PubMed ↗

Roles of autophagy in brain homeostasis and disease.

This narrative review summarized how macroautophagy and related lysosome-dependent recycling pathways maintain brain homeostasis and contribute to neurological disease, emphasizing roles in neurons and glia. It integrates evidence that genetic variants in autophagy genes cause Mendelian nervous system disorders, underscoring autophagy’s causal relevance to CNS pathology. The scientific significance is that it frames autophagy as a mechanistic hub for therapeutic targeting across brain diseases.

Kim H, Wickstead ES, Zhou X et al. · Nature neuroscience · (2026) · View on PubMed ↗

Towards precision psychiatry: initial foundations and future directions.

This Perspective reviewed the emerging precision psychiatry framework, focusing on how biomarker-driven, patient-specific measures (e.g., EEG, objective behavioral assays, fMRI, and peripheral biomarkers) can map neural dysfunction to treatment selection. It argues that aligning therapeutic development with underlying neural biology—analogous to precision oncology/neurology—can overcome slow progress from symptom-only diagnostic systems. Clinically, this supports a roadmap for biomarker-guided drug development and personalized treatment matching in psychiatric disorders.

Etkin A, O’Donnell P, Ressler KJ et al. · Nature reviews. Drug discovery · (2026) · View on PubMed ↗

Lipid-manager autophagy proteins ATG2 and ATG9 regulate extracellular vesicle secretion via amphisome biogenesis and cell lipidome modulation.

This study examined the autophagy lipid-supply proteins ATG2 and ATG9 family members (ATG9A and ATG2A/B) in cultured cells to determine how they regulate extracellular vesicle (EV) secretion through amphisome biogenesis and lipidome modulation. It showed that deleting ATG9A or ATG2A/B increases RAB27A-dependent secretion of smaller CD63-enriched sEVs and causes accumulation of intraluminal vesicles in multivesicular endosomes, linking autophagosome biogenesis to EV output control. The results mechanistically connect specific ATG genes to EV biogenesis pathways, suggesting potential targets to modulate EV-mediated signaling in disease.

Singh A, Johnson DJ, Kuhn J et al. · Nature communications · (2026) · View on PubMed ↗

Balancing Benefits and Risks: Long-term Use of Daily versus Intermittent Corticosteroids in Duchenne Muscular Dystrophy.

This real-world retrospective study compared long-term outcomes of daily versus intermittent corticosteroid regimens in Duchenne muscular dystrophy (DMD), using Belgian and Dutch neuromuscular center data from 1995–2022. It found that intermittent corticosteroid use (10 days on/off) versus daily deflazacort or prednisone/deflazacort showed differential effects across motor, pulmonary, cardiac, anthropometric, and bone health domains over extended follow-up. The findings support more nuanced risk–benefit selection of corticosteroid schedules to balance long-term efficacy with cumulative side effects.

Ikelaar NA, Stoop MHP, van der Holst M et al. · Journal of neurology, neurosurgery, and psychiatry · (2026) · View on PubMed ↗

Childhood trauma and suicide ideation and attempts: Examining the mediating role of psychosocial, personality, lifestyle and biological factors.

This study analyzed data from 1572 participants with a 12-month depressive and/or anxiety disorder in the Netherlands Study of Depression and Anxiety to test how childhood trauma (CT) relates to suicide ideation (SI) and suicide attempts (SA), and whether pathways differ between SI-only (SI+SA-) and SI with attempt (SI+SA+). Using single and multiple mediator models, it evaluated psychosocial, personality, lifestyle, and biological factors as mediators of CT–suicidality associations. The results clarify which intermediate factors may be most actionable for preventing progression from ideation to attempts in clinically vulnerable groups.

Wiebenga JXM, Lokhorst L, Hoogendoorn AW et al. · Journal of affective disorders · (2026) · View on PubMed ↗

GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.

This review synthesized evidence on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in ocular disease, integrating mechanistic, preclinical, and clinical findings. It concluded that GLP-1 RAs may offer therapeutic promise via anti-inflammatory, antioxidative, and vascular/neuroprotective pathways while also identifying emerging safety signals that warrant long-term ocular monitoring. The review frames how GLP-1 RA biology could support ophthalmic repurposing and guides future safety-focused studies.

Conforti A, Cifuentes-González C, Agrawal KR et al. · Drug discovery today · (2026) · View on PubMed ↗

Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

This randomized, double-blind, placebo-controlled phase 2 trial evaluated alixorexton, a selective orexin 2 receptor agonist (OX2R), for safety, tolerability, and efficacy in adults with narcolepsy type 1 across 46 sites in the USA, Europe, and Australia. The key finding was the trial’s assessment of alixorexton’s efficacy on wakefulness and cataplexy measures alongside its overall tolerability profile compared with placebo. The significance is that it advances a next-generation OX2R agonist candidate for narcolepsy type 1 with potential to improve daytime alertness and reduce cataplexy.

Plazzi G, Grunstein RR, Mignot E et al. · The Lancet. Neurology · (2026) · View on PubMed ↗

Pharmacogenetic variants in the molecular characterization initiative: a report from the children’s oncology group.

The study characterized the frequency of clinically actionable pharmacogenetic variants in pediatric cancer patients enrolled in the Children’s Oncology Group (COG) Molecular Characterization Initiative. Using germline exome sequencing and Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for 13 genes, it assessed actionable pharmacogenomic diplotypes in this cohort. This is significant because it quantifies how often pharmacogenomic variants occur in real-world pediatric oncology testing, informing implementation of genotype-guided therapy.

Haidar CE, Yang W, Harris RD et al. · Journal of the National Cancer Institute · (2026) · View on PubMed ↗

Ferroptotic stress promotes hematopoietic stem cell aging through S1P-dependent epigenetic and lipid remodeling.

The study examined how ferroptotic stress drives hematopoietic stem cell (HSC) aging and defined the S1P-dependent epigenetic and lipid remodeling pathway involved. It found that increased sphingosine metabolism elevates sphingosine-1-phosphate (S1P), suppresses HDAC activity to enhance H3K9 acetylation, and upregulates Lpcat2 to promote pro-ferroptotic phospholipid accumulation in aged HSCs, with genetic or pharmacologic Sphk2 inhibition reducing these effects. This is significant because it links ferroptosis to stem cell aging through a druggable Sphk2–S1P–epigenetic–lipid axis, offering potential rejuvenation targets.

Zhao Y, Li Y, Tian X et al. · Blood · (2026) · View on PubMed ↗

Early administration of calcineurin inhibitors limits tolerogenic effect of PTCy in allogeneic hematopoietic transplant.

This study examined how early calcineurin inhibitor (CNI) administration—specifically cyclosporine—affects donor T-cell exhaustion and tolerance induction in a mouse model of haploidentical allogeneic hematopoietic cell transplantation (allo-HCT) using posttransplant cyclophosphamide (PTCy). Early cyclosporine given before PTCy preserved Ly6C+ donor T-cell populations and limited the exhaustion/tolerance effects typically promoted by PTCy, thereby undermining tolerogenic outcomes. These findings suggest that in CNI-containing clinical allo-HCT regimens, timing of cyclosporine relative to PTCy may critically influence T-cell exhaustion and chronic graft-versus-host disease (cGVHD) risk.

Kojima K, Senjo H, Tsukamoto S et al. · Blood · (2026) · View on PubMed ↗

Ciliary ARL13B Drives Cystogenesis in the Kidney via Its GEF Activity.

This study examined the role of the ciliary GTPase ARL13B in kidney cystogenesis, testing whether ARL13B’s guanine nucleotide exchange factor (GEF) activity drives cyst formation in models relevant to polycystic kidney disease. Using ARL13B functional perturbations, the authors showed that ARL13B promotes cystogenesis through its GEF activity toward ARL3, placing the ARL13B–ARL3 signaling axis within the cilia-dependent cyst activation (CDCA) pathway. The results identify a specific ciliary molecular driver that could be exploited to develop targeted therapies for PKD beyond PKD1/PKD2 mutation status.

Van Sciver RE, Forster A, Lewis LM et al. · Journal of the American Society of Nephrology : JASN · (2026) · View on PubMed ↗

Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome.

This international multicenter retrospective cohort study evaluated whether local prevalence of alpha-gal syndrome (AGS) and allergic transfusion reactions (ATRs) are associated in blood type O recipients receiving platelet or plasma transfusions from 2020–2024. It tested the hypothesis that geographic AGS prevalence correlates with ATR rates, motivated by case reports implicating B antigen-containing blood products in anaphylactic reactions in patients with preformed IgE to galactose-α-1,3-galactose (alpha-gal). The epidemiologic results are clinically important for transfusion risk stratification and for guiding whether alpha-gal–related screening or product selection should be considered in high-prevalence regions.

Kaufman RM, Hoen AG, Khan J et al. · JAMA internal medicine · (2026) · View on PubMed ↗

Postural Orthostatic Tachycardia Syndrome (POTS): A Review.

This JAMA review summarized current understanding and diagnostic criteria for postural orthostatic tachycardia syndrome (POTS), a chronic autonomic disorder characterized by excessive orthostatic tachycardia and multisystem symptoms. It highlighted consensus diagnostic thresholds—such as a sustained heart rate increase of at least 30 beats/min (≥40 beats/min in adolescents 12–19) within 10 minutes of standing or head-up tilt without orthostatic hypotension. The review is clinically significant because it consolidates how to recognize and standardize diagnosis of POTS, supporting more consistent evaluation and management.

Chung TH, Raj SR · JAMA · (2026) · View on PubMed ↗

Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.

This narrative review summarized clinical evidence for regenerative peptides used in tissue repair and chronic pain management, including collagen peptides, BPC-157, thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), GHK-Cu, growth hormone-related peptides, and cibinetide (ARA-290). Across the reviewed agents, the authors synthesized proposed mechanisms, available preclinical/clinical outcomes, safety considerations, and regulatory status for chronic pain indications. The review helps clinicians and researchers map where evidence is strongest versus where safety/efficacy data remain limited for peptide-based regenerative therapies.

Luansritisakul C, Chiang MC, Burns SL et al. · Current pain and headache reports · (2026) · View on PubMed ↗

---

---

Generated automatically on August 26, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.